ArticleHead and neck pathology2026
A Genomic and Epigenetic Comparative Study of Low-grade Biphenotypic Sinonasal Sarcoma with Metachronous and Synchronous High-grade Rhabdomyosarcomatous Transformation.
Article in Head and neck pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiphenotypic sinonasal sarcoma (BSNS) is usually histologically distinguishable in its conventional form based on morphology and ancillary studies. However, a subset of BSNS loses characteristic histologic features over time and instead undergoes high-grade rhabdomyosarcomatous transformation (HGRT). The fact that the driver PAX3 fusion of BSNS overlaps with that of other tumors, e.g., alveolar rhabdomyosarcoma, further complicates this diagnostic dilemma. DNA methylation profiling has emerged as a helpful tool in classifying poorly differentiated malignancies. We sought to investigate whether conventional BSNS and HGRT retain the same epigenetic signature over time. MATERIALS AND
methodsFive pure BSNS samples from the initial diagnostic specimens and 4 HGRT components (3 from the long-term recurrence and 1 synchronous) were collected. An immunohistochemical panel of smooth muscle, skeletal muscle, and neural markers was performed and scored as positive or negative. Molecular analyses included RNA-based (4 cases) and DNA-based (2 cases) next-generation sequencing. DNA methylation profiling using the Illumina Infinium EPICv2 microarray was performed, and the methylomes from paired BSNS and HGRT components were compared with a control cohort of BSNS and various high-grade sarcomas.
resultsThe tumors arose from 3 females and one male with an age range of 38-88 years (median 70.5 years old). The time interval between initial BSNS diagnosis to HGRT was between 0 and 14 years (median 8 years). The BSNS components were diffusely positive for S-100 and SMA (4/4), while the HGRT components were positive for desmin (4/4) myogenin (3/4) and Myo D1 (1/1). By RNA sequencing, 2 showed PAX3::FOXO1 fusion and 2 showed PAX3::MAML3 fusion. Compared to the low-grade BSNS, the HGRT from the same patients acquired additional secondary genomic alterations and significantly more frequent chromosomal arm-level copy number variations. DNA methylation profiling demonstrated that in 3 patients, both low-grade BSNS and HGRT converged with conventional BSNS. In one patient with PAX3::FOXO1 fusion, the HGRT from a late recurrence 14 years since initial diagnosis overlapped epigenetically with embryonal rhabdomyosarcoma.
conclusionThe epigenetic signature of BSNS is usually preserved in cases that underwent HGRT, even after many years from the initial onset of BSNS. However, in rare instances, the HGRT component may display epigenetic divergence over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.